IFNG and hemophagocytic syndrome: Furthermore, blocking both IFN-γ and TNF-α with specific antibodies protected against inflammatory cell death and animal mortality from cytokine shock, sepsis, and hemophagocytic lymphohistiocytosis, in addition to SARS-CoV-2 infection (41).